The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity...
WOBURN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has granted a notice of allowance to Biofrontera Bioscience GmbH for patent application No. 12/520,759 (the ’759 patent), titled “Nanoemulsion Formulation with Improved Stability and Cell Penetration.” Biofrontera Inc. has an exclusive license to market and sell Ameluz®, an FDA-approved drug utilizing the technology covered by the patent, in the U.S.
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries presented data analyses for two of its speciality medicines – ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U – from its dermatology portfolio, providing insights to healthcare providers treating patients who have or are at risk for different types of skin cancer. These data analyses were presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the European Commission (EC) has granted marketing authorization for GIVLAARI® (givosiran), an injection for subcutaneous use targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older. AHP is an ultra-rare condition in which patients can experience debilitating attacks of severe abdominal pain, vomiting and seizures, which can be life-threatening due to the possibility of paralysis and respiratory arrest during attacks. Many patients also experience chronic symptoms, including pain, which continue to be present between attacks.
A new treatment hailed as ‘groundbreaking’ has been rolled out across the country as part of the NHS' Long Term Plan, and could see as many as 2,000 patients benefit as a result.
In the run-up to top-line results from a crucial Phase III for its second RNAi drug, Alnylam has solidified an early set of safety and efficacy numbers for givosiran’s data package — part of a rolling submission at the FDA.
A few weeks ago, Alnylam Pharmaceuticals indicated it might seek a speedy FDA approval for what could be the second-ever RNA interference medicine to market. After meeting with regulators, however, the Cambridge, MA, company has come up with a different plan.
Sun pharma's US subsidiary DUSA pharmaceuticals on Wednesday said that the company has filed a law suit against German drug maker Biofrontera for patent infringement, trade secret misappropriation and tortious interference claims in an on going patent infringement suit.
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.